A multicenter retrospective study of patients with pulmonary hypertension transitioned from inhaled to oral treprostinil.

ABSTRACT: Oral treprostinil has recently been shown to delay disease progression in patients with pulmonary arterial hypertension in a long-term outcomes study. The potential advantages of an oral formulation have resulted in patients transitioning from inhaled to oral treprostinil. The current study reports a retrospective analysis of patients who transitioned from treatment with inhaled to oral treprostinil. A multicenter retrospective chart review was conducted for 29 patients with pulmonary hypertension that transitioned from inhaled to oral treprostinil. Data were collected from inhaled treprostinil initiation and patients were followed until discontinuation of oral treprostinil or the end of the observation period. Persistence was calculated using Kaplan-Meier estimates. Prior to transition to

SUBMITTER: Zwicke DL 

PROVIDER: S-EPMC7934059 | biostudies-literature | 2021 Jan-Mar

REPOSITORIES: biostudies-literature